Literature DB >> 10784628

Prognostic impact of trisomies of chromosomes 10, 17, and 5 among children with acute lymphoblastic leukemia and high hyperdiploidy (> 50 chromosomes).

N A Heerema1, H N Sather, M G Sensel, T Zhang, R J Hutchinson, J B Nachman, B J Lange, P G Steinherz, B C Bostrom, G H Reaman, P S Gaynon, F M Uckun.   

Abstract

PURPOSE: Children with acute lymphoblastic leukemia (ALL) and high hyperdiploidy (> 50 chromosomes) have improved outcome compared with other ALL patients. We sought to identify cytogenetic features that would predict differences in outcome within this low-risk subset of ALL patients.
MATERIALS AND METHODS: High-hyperdiploid ALL patients (N = 480) were enrolled between 1988 and 1995 on Children's Cancer Group (CCG) trials. Karyotypes were determined by conventional banding. Treatment outcome was analyzed by life-table methods.
RESULTS: Patients with 54 to 58 chromosomes had better outcome than patients with 51 to 53 or 59 to 68 chromosomes (P = .0002). Patients with a trisomy of chromosome 10 (P<.0001), chromosome 17 (P = .0002), or chromosome 18 (P = .004) had significantly improved outcome compared with their counterparts who lacked the given trisomy. Patients with a trisomy of chromosome 5 had worse outcome than patients lacking this trisomy (P = .02). Patients with trisomies of both chromosomes 10 and 17 had better outcome than those with a trisomy of chromosome 10 (P = .09), a trisomy of chromosome 17 (P =.01), or neither trisomy (P<.0001). Multivariate analysis indicated that trisomy of chromosome 10 (P = .001) was the most significant prognostic factor for high-hyperdiploid patients, yet trisomy of chromosome 17 (P =.02) or chromosome 5 (P = .01) and modal chromosome number (P = .02) also had significant multivariate effects.
CONCLUSION: Trisomy of chromosomes 10 and 17 as well as modal chromosome number 54 to 58 identify subgroups of patients with high-hyperdiploid ALL who have a better outcome than high-hyperdiploid patients who lack these cytogenetic features. Trisomy of chromosome 5 confers poorer outcome among high-hyperdiploid patients.

Entities:  

Mesh:

Year:  2000        PMID: 10784628     DOI: 10.1200/JCO.2000.18.9.1876

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  29 in total

Review 1.  Beyond the 2008 World Health Organization classification: the role of the hematopathology laboratory in the diagnosis and management of acute lymphoblastic leukemia.

Authors:  Stephanie McGregor; Jennifer McNeer; Sandeep Gurbuxani
Journal:  Semin Diagn Pathol       Date:  2012-02       Impact factor: 3.464

2.  Genetic landscape of high hyperdiploid childhood acute lymphoblastic leukemia.

Authors:  Kajsa Paulsson; Erik Forestier; Henrik Lilljebjörn; Jesper Heldrup; Mikael Behrendtz; Bryan D Young; Bertil Johansson
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-22       Impact factor: 11.205

Review 3.  Molecular diagnosis and risk-adjusted therapy in pediatric hematologic malignancies: a primer for pediatricians.

Authors:  Judith Frances Margolin
Journal:  Eur J Pediatr       Date:  2011-02-25       Impact factor: 3.183

4.  Histone methyltransferase EZH2 induces Akt-dependent genomic instability and BRCA1 inhibition in breast cancer.

Authors:  Maria E Gonzalez; Matthew L DuPrie; Heather Krueger; Sofia D Merajver; Alejandra C Ventura; Kathy A Toy; Celina G Kleer
Journal:  Cancer Res       Date:  2011-03-15       Impact factor: 12.701

5.  Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia.

Authors:  James B Nachman; Nyla A Heerema; Harland Sather; Bruce Camitta; Erik Forestier; Christine J Harrison; Nicole Dastugue; Martin Schrappe; Ching-Hon Pui; Giuseppe Basso; Lewis B Silverman; Gritta E Janka-Schaub
Journal:  Blood       Date:  2007-05-01       Impact factor: 22.113

Review 6.  Cytogenetics and molecular genetics of acute lymphoblastic leukemia.

Authors:  Krzysztof Mrózek; David P Harper; Peter D Aplan
Journal:  Hematol Oncol Clin North Am       Date:  2009-10       Impact factor: 3.722

Review 7.  A robust in vivo model for B cell precursor acute lymphoblastic leukemia.

Authors:  Terry J Fry; Peter D Aplan
Journal:  J Clin Invest       Date:  2015-08-24       Impact factor: 14.808

8.  Evolutionary trajectories of hyperdiploid ALL in monozygotic twins.

Authors:  C M Bateman; D Alpar; A M Ford; S M Colman; D Wren; M Morgan; L Kearney; M Greaves
Journal:  Leukemia       Date:  2014-06-04       Impact factor: 11.528

9.  Antimetabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: a report from Children's Oncology Group Study P9201.

Authors:  Allen R Chauvenet; Paul L Martin; Meenakshi Devidas; Stephen B Linda; Beverly A Bell; Joanne Kurtzberg; Jeanette Pullen; Mark J Pettenati; Andrew J Carroll; Jonathan J Shuster; Bruce Camitta
Journal:  Blood       Date:  2007-04-18       Impact factor: 22.113

10.  Hsa-mir-125b-2 is highly expressed in childhood ETV6/RUNX1 (TEL/AML1) leukemias and confers survival advantage to growth inhibitory signals independent of p53.

Authors:  N Gefen; V Binder; M Zaliova; Y Linka; M Morrow; A Novosel; L Edry; L Hertzberg; N Shomron; O Williams; J Trka; A Borkhardt; S Izraeli
Journal:  Leukemia       Date:  2009-11-05       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.